1 Singh N, Husain S, Practice ASTIDCo. Aspergillosis in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:228–41.
2 Eriksson M, Lemstrom K, Suojaranta-Ylinen R, et al. Control of early Aspergillus mortality after lung transplantation: outcome and risk factors. Transplant Proc. 2010;42(10):4459–64.
3 Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients? Curr Opin Infect Dis. 2013;26(4):317–25.
4 Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.
5 Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220–9.
6 Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.
7 Lee JW, Petersen ME, Lin P, Dressler D, Bekersky I. Quantitation of free and total amphotericin B in human biologic matrices by a liquid chromatography tandem mass spectrometric method. Ther Drug Monit. 2001;23(3):268–76.
8 Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003;3(12):772–85.
9 Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother. 1985;27(5):868–71.
10 Mohr JF, Hall AC, Ericsson CD, Ostrosky-Zeichner L. Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation. Pharmacotherapy. 2005;25(3):426–8.
11 Burke D, Lal R, Finkel KW, Samuels J, Foringer JR. Acute amphotericin B overdose. Ann Pharmacother. 2006;40(12):2254–9.
12 Groeneveld S, Verweij PE, Hek LV, Bokkerink JP, Warris A. Amphotericin B-deoxycholate overdose due to administration error in pediatric patients. Med Mycol. 2008;46(2):185–7.
13 Egito ES, Araujo IB, Damasceno BP, Price JC. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity. J Pharm Sci. 2002;91(11):2354–66.
14 Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46(3):828–33.
15 Cleary JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp T. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother. 1993;27(6):715–9.
16 Wang GS, Banerji S, Roussil TK, Heard KJ. Survival after amphotericin B overdose treated with plasmapheresis. Ann Pharmacother. 2013;47(2):e9.
17 Groot OA, Trof RJ, Girbes AR, Swart NL, Beishuizen A. Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B. Neth J Med. 2008;66(10):433–7.
18 Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy. 1998;18(4):874–6.
19 Koren G, Lau A, Kenyon CF, Kroppert D, Klein J. Clinical course and pharmacokinetics f ollowing a massive overdose of amphotericin B in a neonate. J Toxicol Clin Toxicol. 1990;28(3):371–8.